Changing spectrum of invasive fungal infections

Mikologia Lekarska

Volumn 11, Issue 2, 2004, Pages 109-111

  Uzun, Omrum ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Aspergillosis; Candidosis; Invasive fungal infections; Transplant

Indexed keywords

FLUCONAZOLE;

ASPERGILLOSIS; AUTOPSY; CANDIDIASIS; CHEMOPROPHYLAXIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MOULD; MYCOSIS; OPPORTUNISTIC INFECTION; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 9144250529     PISSN: 1232986X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Beck-Sague C.M., Jarvis W.R.: The National Nosocomial Infections Surveillance System: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis., 1993, 167, 1247-1251.
2. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K.: Trends in postmortem epidemiology of invavise fungal infections at a university hospital. J. Infect., 1996, 33, 23-32.
3. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002, 34, 909-917.
4. Baddley J.W., Stroud T.P., Salzman D., Pappas P.G.: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis., 2001, 32, 1319-1324.
5. Crippa F., Holmberg I., Carter R.A., et al.: Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol. Blood Marr. Transplant., 2002, 8, 281-289.
6. Einsele H.H., Kauffmann-Schneider C., Sinzger C., et al.: Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant., 2000, 25, 757-763.
7. Abi-Said D., Anaissie E.J., Uzun O., Raad I., Pinzcowski H., Vartivarian S.: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis., 1997, 24, 1122-1128.
8. Marr K., Seidel K., Slavin M., et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 2000, 96, 2055-2061.
9. Marr K.A., Seidel K., White T.C., Bowden R.A.: Candidemia in allogeneic blood and bone marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J. Infect. Dis., 2000, 181, 309-316.
10. Nucci M., Colombo A.L., Spector N., Velasco E., Martins C.A., Pulcheri W.: Breakthrough candidemia in neutropenic patients. Clin. Infect. Dis., 1997, 24, 275-276.
11. Girmenia C., Martino P., Cassone A.: Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood, 1996, 87, 838-839.
12. Glasmacher A., Hahn C., Leutner C., et al.: Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses, 1999, 42, 443-451.
13. Krcmery V., Oravcova E., Spanik S., et al.: Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology, risk factors and outcome. J. Antimicrob. Chemother., 1998, 41, 373-380.
14. Uzun O., Ascioglu S., Anaissie E.J., Rex J.H.: Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis., 2001, 32, 1713-1717.
15. Collins L.A., Samore M.H., Roberts M.S., et al.: Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J. Infect. Dis., 1994, 170, 644-652.
16. Briegel J., Forst H., Spill B., et al.: Risk factors for systemic fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis., 1995, 14, 375-382.
17. Singh N., Avery R.K., Munoz P., et al.: Trends in risk-profiles and mortality due to invasive aspergillosis in liver transplant recipients. Clin. Infect. Dis., 2003, 36, 45-52.
18. Fortun J., Martin-Davila P., Moreno S., et al.: Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl., 2002, 8, 1065-1070.
19. Singh N.: The changing face of invasive aspergillosis in liver transplant recipients. Liver Transpl., 2002, 8, 1071-1072.
20. Cenci E., Mencacci A., Del Sero G., et al.: Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type 1 responses. J. Infect. Dis., 1999, 180, 1957-1968.
21. Castaldo P., Stratta R.J., Wood R.P., et al.: Fungal disease in liver transplant recipients: a multivariate analysis of risk factors. Transplant. Proc., 1991, 23, 1517-1519.
22. Wajszczuk C.P., Dummer J.S., Ho M., et al.: Fungal infections in liver transplant recipients. Transplantation, 1985, 40, 347-353.
23. Tollemar J., Ericzon B.-G., Holmberg K., Andersson J.: The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant. Proc., 1990, 22, 242-244.
24. Mora N.P., Cofer J.B., Solomon H., et al.: Analysis of severe infections (INF) after 180 consecutive liver transplants: the impact of amphotericin B prophylaxis for reducing the incidence and severity of fungal infections. Transplant. Proc., 1991, 23, 1528-1530.
25. Singh N.: Changing spectrum of invasive candidiasis and its therapeutic implications. Clin. Microbiol. Infect., 2001, 7, Suppl. 2, 1-7.
26. Castro J., Samore M.H., Hadley S., Lewis H.D., Jenkins R.I., Karchmer A.W.: Development and validation of a prediction rule for invasive fungal infection in liver transplant recipients. [in:] 38th International Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 1998, abstract: K-39.
27. Archibald L.K., Phillips L., McGowan J.H. Jr., Tenover F., Gaynes R.: Antimicrobial resistance in isolates for inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin. Infect. Dis., 1997, 24, 211-215.
28. Berrouane Y.F., Herwaldt L.A., Pfaller M.A.: Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J. Clin. Microbiol., 1999, 37, 531-537.
29. Gleason T.G., May A.K., Caparelli D., Fair B.M., Sawyer M.D.: Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch. Surg., 1997, 132, 1197-1202.